+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Anticoagulation Therapy Market, By Product Type, Service, By Clinic: Trend Analysis,, Competitive Market Share & Forecast, 2018-2028

  • PDF Icon


  • 116 Pages
  • July 2022
  • Region: United States
  • Blueweave Consulting & Research Pvt Ltd
  • ID: 5647196

US Anticoagulation Therapy Market to Grow at a CAGR of 7.9% until 2028

United States Anticoagulation Therapy Market is flourishing owing to the growing rates of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and significant recurrent sales of anticoagulation medications; and increased demand for innovative oral anticoagulants (NOACs) are all contributing factors.

A recent study conducted revealed that the United States Anticoagulation Therapy Market was worth USD 23.15 billion in the year 2021. The market is projected to grow at a CAGR of 7.9%, earning revenues of around USD 39.43 billion by the end of 2028. The United States Anticoagulation Therapy Market is booming because of the rising outpatient anticoagulation therapy, rising pipeline products in clinical trials, and rising heparin trade are driving the growth of the anticoagulation therapy market. These factors are also driving up the prevalence of blood vessel thromboembolism, arrhythmia, and stroke as well as the acceptance of NOACs. Moreover, for oncology patients whose risk of blood activation and thrombotic events varies depending on the type of cancer, anticoagulant therapy with heparin and heparin-like medications, vitamin K antagonists, or Direct Oral Anticoagulants gives prolonged life expectancy. Furthermore, the rising prevalence of cardiovascular diseases and blood disorders, high levels of medication adherence associated with clinics, and an aging population are driving growth in the anticoagulation therapy market. However, the target market is projected to be negatively impacted by the high cost of drug development and the potential of malfunctions such as increased bleeding.

Innovation in Blood Thinners and Greater Awareness

Two significant variables impacting the growth of the US market are the rise in cardiovascular health awareness and the subsequent rise in innovative pharmacological releases. Drugs that thin the blood are an essential component of the therapy plan. Cardiovascular therapy includes a broad approach that could lead to the recommendation of many different kinds of drugs. The urgent treatment needs for blood clot prevention have led several key market players to introduce a variety of anticoagulants.

Increasing Demand for New Therapies

The increasing usage of novel oral anticoagulants (NOACs) and rising knowledge of NOACs in developing nations are both positive trends in the market for anticoagulant drugs. The market is anticipated to grow as a result of the escalating geriatric population and the expanding demand for cutting-edge medical procedures. Novel medicines, usually referred to as new molecular entities or new compounds, are chemicals that are distinct from any prescription product that has previously obtained approval from the US Food and Drug Administration (FDA). These drugs are state-of-the-art products that offer a novel method of treating particular medical conditions. Additionally, the prevalence of cardiovascular issues and venous thromboembolism (VTE) has generated a significant growth prospect for the sector.


Because of the long-term ill effects created by chemically compounded medications, people are becoming more cautious about using them, which has posed a hurdle to the market's expansion. The surge in manufacturer competition and the variety of goods has also shown to be obstacles to the market expansion for anticoagulant products during the anticipated timeframe.

Segmental Coverage

United States Anticoagulation Therapy Market - By Clinic

The United States Anticoagulation Therapy Market is divided into three types of clinics: Independent Clinics, Hospital Associated Clinics, and Pharmacy-Based Clinics. The section of these clinics that are located in pharmacies has the biggest market share. In the US during the past few years, the number of anticoagulation clinics housed in pharmacies has significantly increased. This is because treatment overseen by competent pharmacists performs better than care provided by family physicians. Because pharmacy-based anticoagulation clinics offer lower therapy costs than independent and hospital-affiliated anticoagulation clinics, the market for these clinics is expected to expand.

Impact of COVID-19 on United States Anticoagulation Therapy Market

The COVID-19 pandemic is expected to have a significant impact on the anticoagulant industry due to the increasing pace of research. Anticoagulant efficacy in COVID-19 patients is currently being studied in clinical trials. As a result, the COVID-19 pandemic will have both direct and indirect market implications. Furthermore, patients infected with COVID-19, both suspected and confirmed, must receive follow-up care that includes a low dose of anticoagulants, according to a World Health Organization update issued in January 2021. As a result, demand for anticoagulants rose during the pandemic and is expected to rise further during the forecast period (2022-2028).

Competitive Landscape

The leading market players in the United States Anticoagulation Therapy Market are Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Portola Pharmaceuticals, C.H. Boehringer Sohn, Daiichi Sankyo, Abbott, Siemens, Roche, Alere, and other prominent players. The United States Anticoagulation Therapy Market is highly fragmented with the presence of several manufacturing companies in the country. The market leaders retain their supremacy by spending on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Don’t miss the business opportunity in the United States Anticoagulation Therapy Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the United States Anticoagulation Therapy Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the United States Anticoagulation Therapy Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

This product will be delivered within 2 business days.

Table of Contents

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Products
2.2. Quantitative Research
2.2.1. Primary and Secondary Products
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Market Breakdown & Data Triangulation
3. Executive Summary
4. United States Anticoagulation Therapy Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining End-use Industry of Suppliers
4.3.2. Bargaining End-use Industry of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Intensity of Rivalry
4.4. Recent Development
4.5. PESTEL Analysis
5. United States Anticoagulation Therapy Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product Type Drugs Novel Oral Anticoagulants (NOAC’s) Warfarin (VKA) PT/INR Testing Devices In-Office Testing Devices Analyzers Reagents and Kits Home Testing Devices Service Testing Services Consulting Services
5.2.2. By Clinic Hospital Associated Clinic Independent Clinics Pharmacy-Based Clinics
6. Competitive Landscape
6.1. List of Key Players and their Offerings
6.2. Company Market Share Analysis, 2021
6.3. Competitive Benchmarking, By Operating Parameters
6.4. Key Strategic Development (Merger, Acquisition, Partnership, etc.)
7. Impact of Covid-19 Across Anticoagulation Therapy Market
8. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)
8.1. Bristol-Myers Squibb
8.2. Johnson & Johnson
8.3. Pfizer
8.4. Portola Pharmaceuticals
8.5. C.H. Boehringer Sohn
8.6. Daiichi Sankyo
8.7. Abbott
8.8. Siemens
8.9. Roche
8.10. Alere
8.11. Other Prominent Players
9. Key Strategic Recommendations
Financial information in case of non-listed companies will be provided as per availability
The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable
List Of Figures
Figure 1 U.S. Pet Insurance Segmentation
Figure 2 United States Anticoagulation Therapy Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2021
Figure 4 United States Anticoagulation Therapy Market Size, By Value (USD Million), 2018-2028
Figure 5 United States Anticoagulation Therapy Market Share, By Product Type, By Value, 2018-2028
Figure 6 United States Anticoagulation Therapy Market Share, By Clinic, By Value, 2018-2028
List Of Tables
Table 1 United States Anticoagulation Therapy Market Size, By Product Type, By Value, 2018-2028
Table 2 United States Anticoagulation Therapy Market Size, By Clinic, By Value, 2018-2028
Table 3 Bristol-Myers Squibb Company Overview
Table 4 Bristol-Myers Squibb Financial Overview
Table 5 Johnson & Johnson Company Overview
Table 6 Johnson & Johnson Financial Overview
Table 7 Pfizer Company Overview
Table 8 Pfizer Financial Overview
Table 9 Portola Pharmaceuticals Company Overview
Table 10 Portola Pharmaceuticals Financial Overview
Table 11 C.H. Boehringer Sohn Company Overview
Table 12 C.H. Boehringer Sohn Financial Overview
Table 13 Daiichi Sankyo Company Overview
Table 14 Daiichi Sankyo Financial Overview
Table 15 Abbott Company Overview
Table 16 Abbott Financial Overview
Table 17 Siemens Company Overview
Table 18 Siemens Financial Overview
Table 19 Roche Company Overview
Table 20 Roche Financial Overview
Table 21 Alere Company Overview
Table 22 Alere Financial Overview